Is APTO or JEPQ a better dividend investment in 2026?

APTO currently yields 116.96% with a 5% 5-year dividend growth rate. JEPQ yields 11.10% with 5% growth. The better choice depends on your goal: APTO offers higher current income.

What is the dividend yield difference between APTO and JEPQ?

APTO has a forward dividend yield of 116.96% ($2.00/share annually). JEPQ yields 11.10% ($6.16/share annually). The yield gap is 105.86 percentage points.

Home › Compare › APTO vs JEPQ

APTO vs JEPQ: Dividend Comparison 2026

APTO yields 116.96% · JEPQ yields 11.10%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 APTO wins by $7.57M in total portfolio value

INVESTMENT

TIME HORIZON10 years

APTO

● Live price

116.96%

Share price

$1.71

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$7.61M

Annual income

$2,839,061.37

Full APTO calculator →

JEPQ

JPMorgan Nasdaq Equity Premium Income ETF

● Live price

11.10%

Share price

$55.52

Annual div

$6.16

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$44.8K

Annual income

$2,152.59

Full JEPQ calculator →

Portfolio growth — APTO vs JEPQ

📍 APTO pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	APTO	JEPQ
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, APTO + JEPQ cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

APTO pays

JEPQ pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

APTO

Annual income on $10K today (after 15% tax)

$9,941.52/yr

After 10yr DRIP, annual income (after tax)

$2,413,202.16/yr

JEPQ

Annual income on $10K today (after 15% tax)

$943.83/yr

After 10yr DRIP, annual income (after tax)

$1,829.70/yr

At 15% tax rate, APTO beats the other by $2,411,372.46/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of APTO + JEPQ for your $10,000?

APTO: 50%JEPQ: 50%

100% JEPQ50/50100% APTO

Portfolio after 10yr

$3.83M

Annual income

$1,420,606.98/yr

Blended yield

37.10%

📊

Analyst Conviction Gap

Where Wall Street is most bullish on APTO right now

APTO

Analyst Ratings

Buy

Hold

Consensus: Buy

Altman Z

-114.1

Piotroski

3/9

JEPQ

No analyst data

Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

APTO buys

JEPQ buys

No recent congressional trades found for APTO or JEPQ in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricAPTOJEPQ

Forward yield	116.96% ✓	11.10%
Annual dividend / share	$2.00	$6.16 ✓
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	0%
Portfolio after 10y	$7.61M	$44.8K ✓
Annual income after 10y	$2,839,061.37 ✓	$2,152.59
Total dividends collected	$6.91M	$16.3K ✓
Payment frequency	quarterly	monthly
Sector	Stock	ETF

Year-by-year: APTO vs JEPQ ($10,000, DRIP)

Year	APTO Portfolio	APTO Income/yr	JEPQ Portfolio	JEPQ Income/yr	Gap
1← crossover	$22,396	$11,695.91	$11,930	$1,110.39	+$10.5K → APTO
2	$48,444	$24,480.41	$14,133	$1,224.34	+$34.3K → APTO
3	$101,324	$49,488.77	$16,632	$1,340.46	+$84.7K → APTO
4	$205,154	$96,737.39	$19,454	$1,457.97	+$185.7K → APTO
5	$402,568	$183,053.76	$22,626	$1,576.08	+$379.9K → APTO
6	$766,451	$335,702.65	$26,175	$1,694.09	+$740.3K → APTO
7	$1,417,434	$597,331.71	$30,133	$1,811.32	+$1.39M → APTO
8	$2,549,060	$1,032,405.58	$34,531	$1,927.17	+$2.51M → APTO
9	$4,462,671	$1,735,176.87	$39,403	$2,041.08	+$4.42M → APTO
10	$7,614,120	$2,839,061.37	$44,787	$2,152.59	+$7.57M → APTO

APTO vs JEPQ: Complete Analysis 2026

APTO — Stock

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States. Its clinical programs include APTO-253, which is in Phase 1a/b clinical trial for the treatment of patients with relapsed or refractory blood cancers, including acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR MDS); and HM43239 that is in Phase 1/2 clinical trial to treat patients with relapsed or refractory AML. The company also develops luxeptinib, which is in Phase 1a/b clinical trial for treating patients with relapsed or refractory B-cell malignancies, including chronic lymphocytic leukemia, small lymphocytic lymphoma, and various non-Hodgkin's lymphomas, as well as AML and HR MDS; and APL-581, a dual bromodomain and extra-terminal domain motif protein and kinase inhibitor program. It has agreements with CrystalGenomics, Inc. and OHM Oncology. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was incorporated in 1986 and is headquartered in Toronto, Canada.

Full APTO Calculator →

JEPQ — ETF

The fund seeks to achieve this objective by (1) creating an actively managed portfolio of equity securities comprised significantly of those included in the fund’s primary benchmark, the Nasdaq-100 Index (the Benchmark), and (2) through equity-linked notes (ELNs), selling call options with exposure to the Benchmark. It is non-diversified.

Full JEPQ Calculator →

📬

Get this APTO vs JEPQ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

APTO vs SCHD APTO vs JEPI APTO vs O APTO vs KO APTO vs MAIN APTO vs XYLD APTO vs QYLD APTO vs VYM

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.